In Brief Justin Leung receives $1.9 million in funds to research DNA damage response September 11, 2020Vol.46 No.34
Letter To The Editor A reminder: The real goal is saving lives September 11, 2020Vol.46 No.34By Frances M. Visco
Guest Editorial Toward individualized breast cancer screening strategies—TMIST September 11, 2020Vol.46 No.34By Etta D. Pisano, Constantine A. Gatsonis, Peter J. O'Dwyer and Mitchell D. Schnall
Conversation with The Cancer Letter Mitch Schnall: “We don’t want to lose momentum as this review is happening” September 11, 2020Vol.46 No.34By Paul Goldberg
Drugs & Targets Onureg oral therapy receives FDA approval for continued treatment for adults in first remission with AML September 04, 2020Vol.46 No.33
Drugs & Targets Kyprolis and Darzalex receives FDA approval for combination therapy for multiple myeloma September 04, 2020Vol.46 No.33
Drugs & Targets Blenrep receives FDA approval in relapsed or refractory multiple myeloma September 04, 2020Vol.46 No.33
Drugs & Targets Guardant360 CDx assay receives FDA approval as first liquid biopsy NGS companion diagnostic test September 04, 2020Vol.46 No.33
